Journal of drugs in dermatology : JDD · 2025
Squamous Cell Carcinoma In Situ on High-Risk Sites and With Larger Sizes Require More Stages for Clearance With Mohs Surgery.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Steinman Howard K, Dixon Anthony J
Аннотация
BACKGROUND: Few studies have evaluated Mohs micrographic surgery (MMS) for the treatment of squamous cell carcinoma in situ or evaluated the results by Mohs Appropriate Use Criteria.
OBJECTIVE: Evaluate the clinical and surgical characteristics of squamous cell carcinoma in situ treated with MMS and categorize the results by Mohs Appropriate Use Criteria.
METHODS AND MATERIALS: A single Mohs surgeon, prospective, longitudinal cohort study of all squamous cell carcinoma in situ tumors treated with MMS between April 2018 and May 2021.
RESULTS: A total of 485 tumors were treated and 96.9% were primary tumors. Mean age of patients was 73.8 years; 80.6% were male. Mean tumor length, wound length, and subclinical extension were 0.98 cm, 1.58 cm, and 0.7 cm, respectively. These dimensions were lowest in Area H and highest in Area L. Mean stages to clear margins was 1.14. Area H tumors required significantly more stages than those in Areas M and L (P=0.031).
CONCLUSIONS: Mean tumor and wound sizes, stages to clearance, and subclinical extension were lower than previously reported. Area H tumors required more stages to clearance than those in Areas M and L. Stages to clearance increased with increased tumor size. Curettage before surgery did not decrease the number of required stages to achieve clear tumor margins.
CITATION: Steinman HK, Dixon AJ. Squamous cell carcinoma in situ on high-risk sites and with larger sizes require more stages for clearance with Mohs surgery. J Drugs Dermatol. 2025;24(5):494-497. doi:10.36849/JDD.8609.
OBJECTIVE: Evaluate the clinical and surgical characteristics of squamous cell carcinoma in situ treated with MMS and categorize the results by Mohs Appropriate Use Criteria.
METHODS AND MATERIALS: A single Mohs surgeon, prospective, longitudinal cohort study of all squamous cell carcinoma in situ tumors treated with MMS between April 2018 and May 2021.
RESULTS: A total of 485 tumors were treated and 96.9% were primary tumors. Mean age of patients was 73.8 years; 80.6% were male. Mean tumor length, wound length, and subclinical extension were 0.98 cm, 1.58 cm, and 0.7 cm, respectively. These dimensions were lowest in Area H and highest in Area L. Mean stages to clear margins was 1.14. Area H tumors required significantly more stages than those in Areas M and L (P=0.031).
CONCLUSIONS: Mean tumor and wound sizes, stages to clearance, and subclinical extension were lower than previously reported. Area H tumors required more stages to clearance than those in Areas M and L. Stages to clearance increased with increased tumor size. Curettage before surgery did not decrease the number of required stages to achieve clear tumor margins.
CITATION: Steinman HK, Dixon AJ. Squamous cell carcinoma in situ on high-risk sites and with larger sizes require more stages for clearance with Mohs surgery. J Drugs Dermatol. 2025;24(5):494-497. doi:10.36849/JDD.8609.